Treat-to-target has largely become the preferred method for physicians treating patients with rheumatoid arthritis.
Treat-to-target has largely become the preferred method for physicians treating patients with rheumatoid arthritis.
“I think there’s room for further data and evidence, but in general, I think we use this in our patients for the benefits of joint preservation, enhancing work productivity, improving quality of life, and enhancing the probability of remission,” said John M. Davis, MD, MS, vice chair of Rheumatology at Mayo Clinic.
Dr Davis gave a presentation about this topic at the ARHP Clinical Focus Course at the American College of Rheumatology and Association of Rheumatology Health Professionals annual meeting.
His presentation focused on the importance of this treatment for adults with the disease, as well as the updated ACR guidelines. He also discussed his own perspectives in managing rheumatoid arthritis and common comorbidities.
The main goal of treat-to-target is to have patients achieve remission quickly and safely. The goal of patients with severe rheumatoid arthritis may be to achieve low disease activity, Dr Davis said.
Treat-to-target requires physicians to measure a patient’s disease activity every 1 to 3 months until the desired outcome is reached, and then disease activity is measured every 3 to 6 months. If disease activity becomes unstable, it needs to be monitored more often, and treatment must be adjusted.
However, taking other medications, side effects, cost and health care burdens could also present limitations for this treatment, according to the session. The shift towards treat-to-target was due to the TICORA and BeST clinical trials, which were both conducted in the early 2000s.
At that time, the standard care was a pyramid scheme, Dr Davis said in the session. Physicians would initiate treatment with an NSAID or hydroxychloroquine and then wait 6 months before determining if the patient responded.
The newly-revised ACR guideline expands on an earlier version of the guidelines, now recommending treat-to-target for these patients. The new recommendations were revised using the GRADE methodology that uses a transparent and aggressive assessment of evidence.
Recommendations of treatments are categorized as strong or conditional. A strong recommendation means that a majority of patients should receive it and conditional means that there should be an open discussion about whether this is a beneficial treatment option, according to the session.
The session also discussed what physicians should do if their patients do not achieve the treatment goal, or do not respond to the treatment. For patients who do not respond optimally to methotrexate, there are other strong recommendations for treatments based on clinical trials, and there are also conditional recommendations for patients who fail to respond.
When patients experience treatment failure, barriers to care must be discussed. Factors such as medication adherence, caregiver support, smoking, weight, mental health conditions, and a wrong diagnosis should be discussed in this care, Dr Davis said.
Another issue that can also contribute to depression is if patients and physicians are not in agreement about the disease. If patients believe their disease is less or more severe than their physician does, this discordance can increase the risk of depression.
“Both situations can be problematic, although I think the one that is most challenging for us is the situation in which the patient is struggling and having high levels of pain and disability,” Dr. Davis said.
By implementing a treat-to-target strategy and understanding the new guidelines, physicians have an increased ability to treat patients in the most beneficial manner.
- See more at: http://www.specialtypharmacytimes.com/conferences/acr-2016/target-to-treat-approach-beneficial-for-rheumatoid-arthritis-treatment#sthash.Fzpmud7S.dpuf
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More